Neuroinflammation and Oxidative Stress in the Pathogenesis of Autism Spectrum Disorder

Int J Mol Sci. 2023 Mar 13;24(6):5487. doi: 10.3390/ijms24065487.

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder (NDD) characterized by impairments in social communication, repetitive behaviors, restricted interests, and hyperesthesia/hypesthesia caused by genetic and/or environmental factors. In recent years, inflammation and oxidative stress have been implicated in the pathogenesis of ASD. In this review, we discuss the inflammation and oxidative stress in the pathophysiology of ASD, particularly focusing on maternal immune activation (MIA). MIA is a one of the common environmental risk factors for the onset of ASD during pregnancy. It induces an immune reaction in the pregnant mother's body, resulting in further inflammation and oxidative stress in the placenta and fetal brain. These negative factors cause neurodevelopmental impairments in the developing fetal brain and subsequently cause behavioral symptoms in the offspring. In addition, we also discuss the effects of anti-inflammatory drugs and antioxidants in basic studies on animals and clinical studies of ASD. Our review provides the latest findings and new insights into the involvements of inflammation and oxidative stress in the pathogenesis of ASD.

Keywords: autism spectrum disorder; biomarker; hydrogen; inflammation; maternal immune activation; oxidative stress; silicon; viral infection.

Publication types

  • Review

MeSH terms

  • Animals
  • Autism Spectrum Disorder* / pathology
  • Female
  • Humans
  • Inflammation / complications
  • Neuroinflammatory Diseases
  • Oxidative Stress
  • Pregnancy
  • Prenatal Exposure Delayed Effects*

Grants and funding

This work was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (C) (20K06872) to N.U., Uehara Memorial Foundation to N.U., Takeda Science Foundation to N.U., Mochida Memorial Foundation for Medical and Pharmaceutical Research to N.U., Osaka Medical Research Foundation for Intractable Diseases to N.U., and SENSHIN Medical Research Foundation to N.U.